Myriad Genetics, Inc. (MYGN) earnings
MYGN earnings moved a median of -2.84% by the close. Quarterly and annual MYGN reports and results, each read against the price at its own news timestamp. Back to the MYGN overview →
29 measured MYGN earnings events.
Where these MYGN earnings landedvs 29 measured MYGN earnings reactions
| Middle 50% of MYGN earnings reactions | -4.67% to +2.00% |
|---|---|
| Median reaction (to close) | -2.84% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 MYGN earnings events with a measured close landed between -4.67% and +2.00%; 38% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q MYRIAD GENETICS INC For: Jun 30 | SEC filing · Form 10-Q | +8.00% | -4.67% | |
| Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Press release | +8.00% | -4.67% | |
| Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 | Press release | +3.39% | +1.79% | |
| Form 10-Q MYRIAD GENETICS INC For: Mar 31 | SEC filing · Form 10-Q | +2.01% | -2.84% | |
| Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business | Press release | +2.01% | -2.84% | |
| Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 | Press release | +1.47% | -1.68% | |
| Form 10-K MYRIAD GENETICS INC For: Dec 31 | SEC filing · Form 10-K | +0.45% | +7.90% | |
| Form 10-Q MYRIAD GENETICS INC For: Sep 30 | SEC filing · Form 10-Q | -2.02% | -12.94% | |
| Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution | Press release | -2.02% | -12.94% | |
| Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025 | Press release | +0.37% | +0.99% | |
| Form 10-Q MYRIAD GENETICS INC For: Jun 30 | SEC filing · Form 10-Q | +4.60% | +8.62% | |
| Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum | Press release | +4.60% | +8.62% | |
| Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 | Press release | -1.20% | -2.64% | |
| Form 10-Q MYRIAD GENETICS INC For: Mar 31 | SEC filing · Form 10-Q | -7.11% | -25.09% | |
| Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance | Press release | -7.11% | -25.09% | |
| Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 | Press release | -0.94% | -3.87% | |
| Form 10-K MYRIAD GENETICS INC For: Dec 31 | SEC filing · Form 10-K | -1.20% | -4.24% | |
| Form 10-Q MYRIAD GENETICS INC For: Sep 30 | SEC filing · Form 10-Q | +3.19% | -3.33% | |
| Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance | Press release | +3.19% | -3.33% | |
| Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024 | Press release | +0.83% | +3.50% | |
| Form 10-Q MYRIAD GENETICS INC For: Jun 30 | SEC filing · Form 10-Q | -2.71% | -6.72% | |
| Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% | Press release | -2.71% | -6.72% | |
| Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024 | Press release | +0.33% | +0.76% | |
| Form 10-Q MYRIAD GENETICS INC For: Mar 31 | SEC filing · Form 10-Q | +1.13% | +2.00% | |
| Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA | Press release | +1.13% | +2.00% | |
| Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 | Press release | +0.96% | -1.37% | |
| Form 10-K MYRIAD GENETICS INC For: Dec 31 | SEC filing · Form 10-K | -0.88% | -7.05% | |
| Form 10-Q MYRIAD GENETICS INC For: Sep 30 | SEC filing · Form 10-Q | +6.02% | +3.74% | |
| Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance | Press release | +6.02% | +3.74% |
Keep exploring
More MYGN: analyst actions → · SEC filings → · MYGN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| VICAL (VICL) | 574 | -0.00% | 38% |
| Becton, Dickinson and Company (BDX) | 573 | -0.01% | 50% |
| Tilray Brands, Inc. (TLRY) | 558 | -0.32% | 41% |
| PERNIX THERAPEUTICS HOLDINGS (PTX) | 557 | -0.19% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.